Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022" report to their offering.

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy.

As per report findings, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

Key Topics Covered:

1. Immunotherapy: Mending Cancer Regimens

2. Categorization of Cancer Immunotherapy

3. Fundamentals of Cancer Vaccines

4. New Era of Monoclonal Antibodies

5. Trails of T-Cell Therapies

6. Aspects of Immune Checkpoint Inhibitors

7. Immunomodulators in Cancer Immunotherapy

8. Oncolytic Viral Immunotherapy

9. Cytokines in Cancer Immunotherapy

10. Interferons in Immunotherapy

11. Interleukins in Immunotherapy

12. GM-CSF in Immunotherapy

13. Global Economic Evaluations

14. Market Aspects of Cancer Immunotherapy

15. Global Cancer Immunotherapy Market Dynamics

16. Marketed Cancer Cell Therapies Drugs

17. Marketed Cancer Cytokines Drugs

18. Marketed Cancer Vaccines

19. Marketed Cancer Monoclonal Antibodies

20. Global Cancer Immunotherapy Market Future Prospects

21. Competitive Landscape

- Abbvie

- Advaxis

- Altor BioScience

- Amgen

- Biogen Idec

- Biogenomics

- Celldex Therapeutics

- Dendreon Corporation

- Eli Lilly

- Expression Genetics

- Galena Biopharma

- Genmab

- Gilead

- Sciences

- GlaxoSmithKline

- ImmunoCellular Therapeutics

- ImmunoGen

- Inovio Pharmaceuticals

- IRX Therapeutics

- Merck

- NeoStem Oncology

- NewLink Genetics

- Northwest Biotherapeutics

- Novartis

- Peregrine Pharmaceuticals

- Pfizer

- Philogen

- Regulon

- Roche

- Seattle Genetics

- ZymoGenetics

For more information about this report visit http://www.researchandmarkets.com/research/hpbm7b/global_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Clinical Trials

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Clinical Trials